A Phase 1b Dose Escalation Study of Metabolically Fit CD19 Chimeric Antigen Receptor (CAR) T Cells With CD34 Selection Markers in Adult Patients With Relapsed or Refractory CD19 B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 27
- 试验地点
- 2
- 主要终点
- CRS occurrence evaluation
研究概览
简要总结
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
详细描述
Although CD19 CAR T-cell therapy is a dynamic scientific and clinical breakthrough for CD19+ NHL, issues still remain in terms of relapse, toxicity, and availability. This trial will incorporate a CD34 tag (CD34t) into the CAR T-cell construct, thus allowing a more purified CAR T-cell product via CD34 selection. This purification step will hopefully lead to an improvement in safety/toxicity. Furthermore, the issue of CD19 CAR T-cell relapse has been linked to a lack of CAR T-cell fitness. With the knowledge that Th1 T-cell subsets have improved effector function and Th17 T-cell subsets have improved persistence, the investigators plan to expose the collected T-cells to priming conditions that lead to a metabolically enhanced CAR-T cell product akin to a Th1/17 hybrid cell. The investigators hypothesize that these metabolically programmed CD19 CAR-T cells will yield a high- quality product with enhanced persistence and anti-tumor efficacy when purified based on CD34t expression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients eligible for study participation must meet all of the following criteria:
- •Disease Related Criteria
- •Participants must have histologic confirmation of one of the following:
- •CD19+ aggressive non-Hodgkin lymphoma including any of the following subtypes
- •Diffuse Large B-cell Lymphoma, not otherwise specified
- •DLBCL, germinal-center B-cell type (GCB)
- •DLBCL, activated B-cell type (ABC)
- •T-cell histiocyte-rich B-cell lymphomas (THRBCL)
- •Primary cutaneous DLBCL, leg type
- •Intravascular large B cell lymphoma
- •EBV+ DLBCL, NOS
- •DLBCL associated with chronic inflammation
- •HHV8+ DLBCL, NOS
- •High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement(double hit lymphoma)
- •High grade B-cell lymphoma, NOS
- •Primary mediastinal B-cell lymphoma
- •B-cell Lymphoma, unclassifiable with features intermediate between DLBCL and Hodgkin lymphoma, as well as with features intermediate between DLBCL and Burkitt lymphoma
- •Follicular lymphoma grade 3B
- •Transformation of indolent lymphoma (i.e. CLL, MZL, FL, Waldenstrom's lymphoma,etc) to -diffuse large B-cell lymphoma
- •Burkitt Lymphoma
- •Lymphomatoid granulomatosis
- •CD19+ indolent non-Hodgkin lymphoma including any of the following subtypes:
- •Follicular lymphoma (grade 1-3A)
- •Marginal zone lymphoma: Including splenic marginal zone lymphoma, nodal marginal zone lymphoma, and mucosa associated lymphoid tissue (MALT) lymphoma
- •Waldenstrom's Macrogloublinemia
- •Nodular lymphocyte predominant hodgkin lymphoma (with documented CD19 expression)
- •Mantle cell Lymphoma
- •Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- •Prior Therapy Criteria Prior/Concurrent Therapy Related Criteria (dependent upon subtype - see below)
- •Aggressive lymphoma: patients will qualify if any of the following scenarios are met below (radiation does not count as a line of therapy)
- •Relapse or persistent disease after ≥ 2 lines of systemic therapy OR
- •Refractory disease or relapse within 12 months of completion of 1st line systemic therapy OR
- •Refractory disease or relapse ≥ 1 line of therapy but not a candidate for autologous stem cell transplant
- •Patients with Burkitt lymphoma will qualify after ≥ 1 line of therapy regardless of the timing of relapse
- •Indolent lymphoma:
- •Relapse or persistent disease after ≥ 2 lines of systemic therapy. (Neither single agent rituximab or radiation qualify as a line of therapy.)
- •Mantle cell lymphoma:
- •Relapse or persistent disease after ≥ 1 line of systemic therapy. Neither single agent rituximab or radiation qualify as a line of therapy.
- •Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- •Evidence of progression or intolerance after ≥ 2 lines of therapy. The following will qualify as a line of therapy for CLL/SLL:
- •systemic chemoimmunotherapy (e.g. BR, FCR, etc),
- •BTK inhibitor, BCL-2 inhibitor,
- •or PI3 Kinase inhibitor.
- •Neither single agent rituximab/obinutuzumab or radiation qualify as a line of therapy.
- •Clinical/Laboratory Criteria
- •Participants must be at least 18 years old
- •Participants must have a performance status of 0-2 on the ECOG scale
- •Participants must have adequate caregiving support for CAR T-cell therapy as determined by the PI/Co-I.
- •Participants must have measurable disease on cross section imaging by PET-CT and/or CT scans alone that is at least 1.5 cm in the longest diameter and measurable in two perpendicular dimensions as defined by IWG criteria. If participants with CLL do not have measurable disease on imaging, a bone marrow biopsy showing > 5% CLL involvement in the bone marrow will qualify for enrollment
- •Participants that have received prior CD19 targeted therapy in the past they must have a tissue biopsy after completion of CD19 targeted therapy noting CD19 expression by either flowcytometry or immunohistochemistry (IHC). CD19 expression must be sufficient per PI/Co-I
- 另有 18 项未显示
排除标准
- •Participants eligible for study participation CANNOT meet any of the following criteria:
- •Prior/Concurrent Therapy Related Criteria Guidelines regarding when lymphoma directed therapy should be stopped prior to leukapheresis, lymphodepleting chemotherapy, and CAR T-cell infusion are detailed in the protocol. These criteria must be planned to be met for all patients.
- •Clinical/Laboratory Criteria
- •Women who are pregnant or breast-feeding.
- •Participants with active CNS lymphoma. Participants can have a history of active CNS lymphoma as outline in protocol
- •Participants with evidence of Graft vs Host Disease from allogeneic stem cell transplant are ineligible unless it is either grade 1 involvement of the skin or not requiring systemic immunosuppression.
- •Participants with uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
- •Participants with a history of stroke or intracranial hemorrhage within 6 months prior to registration. Any CNS disorder that would serve as a major barrier in evaluating neurotoxicity/ICANS per enrolling physician
- •Participants with prior history of malignancy other than lymphoma unless subject is free of disease for more than 1 year from signing consent. Exceptions include the following:
- •Basal cell carcinoma of the skin
- •Squamous cell carcinoma of the skin
- •Carcinoma in situ of the cervix or breast
- •Previously treated localized prostate cancer with normal PSA levels
- •Participants with primary immunodeficiency or history of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 1 year.
- •Participants with receipt of live vaccine within 28 days prior to registration.
- •Participants with history of autologous stem cell transplant within the last 60 days or allogeneic stem cell transplant within the last 90 days or CAR T-cell therapy within the last 180 days.
- •Participants with a history of severe immediate hypersensitivity reaction to any of the agents used in the study
- •Participants with any other illness that in the opinion of the investigator, would exclude the patient from participating in this study.
- •Participants must not have evidence of active CNS lymphoma involvement. This includes parenchymal, spinal cord, meningeal, or cerebrospinal fluid involvement. Patients with history of CNS involvement must have documented remission by contrast-enhanced MRI imaging and CSF evaluation for at least 60 days prior to registration.
- •Patients must not have any unstable angina, or myocardial infarction within the last 6 months, or symptoms consistent with NYHA CHF classification III or IV
- •Participants with receipt of live vaccine within 28 days prior to registration.
- •Participants with history of autologous stem cell transplant within the last 60 days or allogeneic stem cell transplant within the last 90 days or CAR T-cell therapy within the last 180days.
- •Participants with a history of severe immediate hypersensitivity reaction to any of the agents used in the study
- •Participants with any other illness that in the opinion of the investigator, would exclude the patient from participating in this study.
研究组 & 干预措施
Dose Level 3
2 x 10^6 transduced T cells/kg (± 20%)
干预措施: Cyclophosphamide injection (Drug)
Dose Level 3
2 x 10^6 transduced T cells/kg (± 20%)
干预措施: CD19-CD34t metabolically programmed CAR transduced T-cells (Biological)
Dose Level 1
1 x 10^6 transduced T cells/kg (± 20%)
干预措施: Cyclophosphamide injection (Drug)
Dose Level 1
1 x 10^6 transduced T cells/kg (± 20%)
干预措施: CD19-CD34t metabolically programmed CAR transduced T-cells (Biological)
Dose Level 2
1.5 x 10^6 transduced T cells/kg (± 20%)
干预措施: CD19-CD34t metabolically programmed CAR transduced T-cells (Biological)
Dose Level 2
1.5 x 10^6 transduced T cells/kg (± 20%)
干预措施: Cyclophosphamide injection (Drug)
Dose Level 1
1 x 10^6 transduced T cells/kg (± 20%)
干预措施: Fludarabine Injection (Drug)
Dose Level 2
1.5 x 10^6 transduced T cells/kg (± 20%)
干预措施: Fludarabine Injection (Drug)
Dose Level 3
2 x 10^6 transduced T cells/kg (± 20%)
干预措施: Fludarabine Injection (Drug)
结局指标
主要结局
CRS occurrence evaluation
时间窗: Duration of study, up to 24 months
Rate of grade 3 or higher cytokine release syndrome(CRS)
MTD/MAD/RP2D evaluation
时间窗: 12 months
Maximum tolerated dose (MTD), maximum administered dose (MAD) and the recommended phase 2 dose (RP2D) of CD19-CD34t metabolically programmed CAR T-cells
ICANS occurrence evaluation
时间窗: Duration of study, up to 24 months
rate of grade 3 or higher immune effector cell-associated neurotoxicity syndrome (ICANS)
次要结局
- Overall response and complete remission rate(12 months)
- Progression free survival, duration of response, overall survival evaluations(12 months)
- ORR and CR evaluation at the RP2D(Duration of study, up to 24 months)
- PFS, DOR and OS evaluation at the RP2D(Duration of study, up to 24 months)
- Safety evaluation at the RP2D(Duration of study, up to 24 months)